Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Romiplostim (Nplate®) is recommended as an option for use within NHS Wales for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments (for example, corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | romiplostim (Nplate®) | ||
| Formulation | 125 micrograms powder for solution for injection | ||
| Reference number | 3103 | ||
| Indication | Treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments (for example, corticosteroids, immunoglobulins) |
||
| Company | Amgen Ltd | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0119 | ||
| NMG meeting date | 09/01/2019 | ||
| AWMSG meeting date | 13/02/2019 | ||
| Date of issue | 05/03/2019 | ||
| Date of last review | April 2022 | ||
| Commercial arrangement | PAS | ||
| Further information Technologies recommended by NICE that include a commercial arrangement (excel) Please refer to NICE TA221 for the romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura in adults. This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||